Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide for rheumatoid arthritis.

M E Suarez-Almazor1, E Belseck, B Shea

  • 1Health Services Research, Veterans Affairs Medical Center, Mailbox Station 152, 2002 Holcombe Blvd, Houston, Texas 77024, USA. mes@bcm.tmc.edu

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary

Cyclophosphamide shows short-term benefits for rheumatoid arthritis patients, improving joint scores. However, severe toxicity limits its use due to a poor benefit-risk ratio compared to other treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.

Communications medicine·2026
Same author

Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors.

Seminars in arthritis and rheumatism·2025
Same author

Early COVID-19 pandemic modeling: Three compartmental model case studies from Texas, USA.

Computing in science & engineering·2022
Same author

A Short Report Examining the Introduction of Routine Use of Patient-Reported Outcome Measures in a Mixed Oncology Population.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same author

The ASAS-OMERACT core domain set for axial spondyloarthritis.

Seminars in arthritis and rheumatism·2021
Same author

<i>trips4health</i>: Protocol of a single-blinded randomised controlled trial incentivising adults to use public transport for physical activity gain.

Contemporary clinical trials communications·2020

Area of Science:

  • Rheumatology
  • Clinical Pharmacology
  • Immunosuppressive Therapy

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and damage.
  • Current treatments aim to manage disease activity and prevent joint destruction.
  • Cyclophosphamide, an alkylating agent, has been explored for its immunomodulatory effects in RA.

Purpose of the Study:

  • To evaluate the short-term efficacy and safety of cyclophosphamide in treating rheumatoid arthritis.
  • To compare cyclophosphamide's effects against placebo in patients with RA.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) and controlled clinical trials (CCTs).
  • Searched major databases (Cochrane, Medline, Embase) up to July 1997.

Related Experiment Videos

  • Pooled analysis of joint counts, erythrocyte sedimentation rate (ESR), and toxicity data using standardized mean differences (SMDs) and odds ratios (ORs).

    • Main Results:

    • Cyclophosphamide significantly improved tender and swollen joint scores (SMDs -0.57 and -0.59, respectively).
    • Erythrocyte sedimentation rate (ESR) showed a trend towards improvement but did not reach statistical significance.
    • Cyclophosphamide reduced the likelihood of developing new or worse erosions (OR=0.17) but was associated with higher rates of withdrawal due to adverse reactions (OR=2.9).

    Conclusions:

    • Cyclophosphamide demonstrates short-term clinical benefits in rheumatoid arthritis disease activity.
    • Its efficacy is comparable to some disease-modifying antirheumatic drugs (DMARDs) but less than methotrexate.
    • Severe toxicity, including hemorrhagic cystitis and myelosuppression, results in a poor benefit-risk ratio, limiting its clinical utility.